Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. reports developments for a global additives and specialty ingredients business serving pharmaceuticals, personal care, food and beverage, architectural coatings, construction, energy and other industrial markets. Company updates commonly cover quarterly results and outlook, segment demand across Life Sciences, Personal Care, Specialty Additives and Intermediates, pricing actions tied to raw-material and logistics conditions, and capital returns through common-stock dividends.
Other Ashland news includes product and regulatory developments for specialty ingredients such as agrimer™ eco-coat polymer seed coating from the Transformed Vegetable Oils technology platform, as well as distribution relationships for cellulose ethers and PVPP in food and beverage applications.
Ashland Inc. (NYSE: ASH) has scheduled its second-quarter fiscal 2025 earnings release for April 30, 2025, at approximately 5 p.m. ET. The company will host a live webcast with securities analysts on May 1, 2025, at 10 a.m. ET.
Key executives participating in the presentation include Chair and CEO Guillermo Novo, CFO Kevin Willis, and several senior vice presidents leading different business segments. The webcast will feature an executive summary and detailed remarks, accompanied by a slide presentation available on the company's investor relations website.
Participants can access the call via phone through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. The webcast and supporting materials will be accessible through Ashland's Investor Relations website and will remain archived for 12 months following the live event.
Ashland has completed a $10 million expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil, with a ribbon-cutting ceremony scheduled for April 4, 2025. The investment aims to meet growing market demand for coated tablets in Latin America, where consumption grew 4.3% annually between 2019-2023, with Brazil reaching 5.7% yearly growth.
The expansion includes modernization of microbial protection equipment at the R&D laboratory in São Paulo, following previous investments in Ireland and China. The new state-of-the-art facilities enhance Ashland's capabilities in tablet coatings application, color matching, stability, and quality evaluation. Local employees received specialized training at US headquarters to ensure optimal performance.
In 2023, Ashland introduced seven new platform technologies focused on sustainable innovations in personal care, pharmaceuticals, and coatings sectors. The company has already launched several patented innovations from their Transformed Vegetable Oils and Super Wetters platforms.
Ashland Inc. (NYSE: ASH) announces its upcoming Innovation Day for analysts and investors, scheduled for May 29, 2025, at their Bridgewater, New Jersey facility. The event will showcase enhanced capabilities and expanded applications of Ashland's scalable technology platforms.
The event, running from 9:00 AM to 11:30 AM ET, will feature presentations from key leadership including Chair and CEO Guillermo Novo and Chief Technology Officer Osama Musa. Participants can attend either in person or via live webcast, with in-person attendees enjoying additional benefits including:
- Lab tours highlighting applications in Life Sciences, Personal Care, and Specialty Additives
- Direct engagement with senior leadership during Q&A sessions
- Networking opportunities with business line leaders and scientists during a luncheon
In-person activities will conclude at approximately 2:00 PM ET. The presentation materials will be available on Ashland's investor website, with replay access for 12 months following the event.
Ashland Inc. (NYSE: ASH) has completed the sale of its Avoca business to Mane on March 14, 2025. The Avoca business, which represents the final entity from Ashland's previous Pharmachem acquisition, specializes in producing sclareolide (a fragrance fixative) and offers contract manufacturing capabilities through facilities in North Carolina and Wisconsin.
While financial terms were not disclosed, the transaction marks a strategic divestment for Ashland. The deal transfers Avoca's manufacturing facilities and its workforce to Mane, whose CEO Samantha Mane expressed commitment to ingredient production through this acquisition. Squire Patton Boggs served as Ashland's legal advisor for the transaction.
Ashland Inc. (ASH) reported Q1 fiscal 2025 financial results with sales of $405 million, down 14% year-over-year. The decline includes an 11% reduction ($50 million) from Portfolio Optimization initiatives. The company reported a net loss of $165 million, or $3.50 per diluted share, compared to net income of $26 million in the prior year.
Adjusted EBITDA was $61 million, down 13% from the prior year, primarily due to Portfolio Optimization, reduced pricing, and increased expenses. The company maintains its full-year fiscal 2025 outlook, expecting sales between $1.90-2.05 billion and Adjusted EBITDA of $430-470 million.
Ashland signed a definitive agreement to sell its Avoca business to Mane and is implementing a $30 million cost reduction plan to offset stranded costs from the nutraceutical business sale.
Ashland (NYSE: ASH) has announced that its board of directors has declared a quarterly cash dividend of $0.405 per share on the company's common stock. The dividend will be paid on March 15, 2025, to stockholders of record as of March 1, 2025. The company reported 47,182,862 outstanding shares of common stock as of December 31, 2024.
Ashland Inc. (NYSE: ASH) has announced it will release its first-quarter fiscal 2025 earnings report on Tuesday, January 28, 2025, at approximately 5 p.m. ET. The company will host a live webcast with securities analysts on Wednesday, January 29 at 9 a.m. ET, featuring an executive summary and detailed remarks.
Key executives participating in the presentation include Chair and CEO Guillermo Novo, CFO Kevin Willis, and several senior vice presidents. A slide presentation will be available simultaneously on the company's Investor Relations website. Participants are encouraged to register for phone access and dial in fifteen minutes before the scheduled start time. The webcast and supporting materials will remain accessible on Ashland's website for 12 months following the live event.
Ashland Inc. (NYSE: ASH) has announced a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in Q1 2025, subject to customary closing conditions. Avoca, which represents the final entity from Ashland's previous Pharmachem acquisition, operates two production facilities in North Carolina and Wisconsin, specializing in Sclareolide (a fragrance fixative) and contract manufacturing capabilities. Squire Patton Boggs is serving as Ashland's legal advisor for this transaction.
Ingevity (NYSE:NGVT) has elected J. Kevin Willis to its board of directors, expanding the board to nine members, with eight being independent. Willis currently serves as senior vice president and CFO at Ashland Inc. (NYSE:ASH), where he oversees worldwide financial functions and participates in global strategy setting. During his 37-year tenure at Ashland, Willis has accumulated extensive experience in accounting, finance, and treasury management, including international operations. His expertise includes driving shareholder value through capital allocation planning, operating efficiencies, and business portfolio separations, notably Ashland's separation from Valvoline.
Ashland Inc. (NYSE: ASH) marked its 100-year anniversary by ringing the opening bell at the New York Stock Exchange on December 9, 2024. CEO Guillermo Novo and company executives participated in this historic tradition that dates back to 1792.
The company has evolved from an oil and refining company to a focused additives and specialty ingredients company. One year ago, Ashland introduced seven new technology platforms aligned with its pharmaceutical, personal care, and specialty additives core, offering sustainable innovations to customers worldwide.
Ashland announced a strategy update event scheduled for December 10, 2024, in New York City. The event will provide an in-depth review of strategic priorities, initiatives, and financial objectives for fiscal year 2025. Despite challenges from inventory destocking in the materials sector, the company achieved margin expansion and high-quality free cash flow.